Safety of apremilast: risk of psychical disorders
Apremilast is a new selective inhibitor of phosphodiesterase 4 (PDE4) of the class of small molecules, approved for treatment of psoriatic arthritis and psoriasis. The efficacy and safety of apremilast in the treatment of moderate to severe plaque psoriasis have been demonstrated in multicenter, ran...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
2018-02-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/89 |